The quest for improved biomarkers to enhance PARP inhibitor response prediction in ovarian cancer patients continues, emphasising the need for standardised methodologies and comprehensive clinical validation to advance precision medicine in ovarian cancer treatment. The gene discussed is PARP1; the disease is ovarian cancer.